For a low-risk patient with a 4 mm to <6 mm pulmonary nodule, what is the recommended next step?

For a low-risk patient with a 4 mm to <6 mm pulmonary nodule, what is the recommended next step?

• A. Immediate contrast-enhanced CT
• B. Observation with no imaging
• C. Repeat noncontrast CT at 12 months
• D. PET-CT

Answer: (C)

Small pulmonary nodules are usually managed based on their size and the patient’s overall risk. For a low-risk person with a 4–6 mm nodule, the likelihood of malignancy is low, so the goal is to monitor rather than jump to invasive testing. The best next step is a repeat noncontrast chest CT at 12 months. This timing balances the chance that a malignant nodule would show growth within a year against the harms of unnecessary immediate imaging. If the nodule is unchanged at 12 months, the probability of cancer is very low and further imaging is typically not needed. If growth or new concerning features appear on follow-up imaging, then more extensive evaluation (such as PET-CT or CT with contrast, or referral) may be warranted. Choosing immediate contrast-enhanced CT or PET-CT isn’t warranted in this low-risk, small-nodule scenario, as these tests add cost, radiation, and may yield false positives without improving decision-making. Observing with no imaging would risk missing early growth that would change management.

Small pulmonary nodules are usually managed based on their size and the patient’s overall risk. For a low-risk person with a 4–6 mm nodule, the likelihood of malignancy is low, so the goal is to monitor rather than jump to invasive testing.

The best next step is a repeat noncontrast chest CT at 12 months. This timing balances the chance that a malignant nodule would show growth within a year against the harms of unnecessary immediate imaging. If the nodule is unchanged at 12 months, the probability of cancer is very low and further imaging is typically not needed. If growth or new concerning features appear on follow-up imaging, then more extensive evaluation (such as PET-CT or CT with contrast, or referral) may be warranted.

Choosing immediate contrast-enhanced CT or PET-CT isn’t warranted in this low-risk, small-nodule scenario, as these tests add cost, radiation, and may yield false positives without improving decision-making. Observing with no imaging would risk missing early growth that would change management.